Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
Condition: Acute Lymphoblastic Leukemia
MeSH terms: Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid
Study type: Interventional
Phase: Phase 1

Summary: 
      Laboratory and other studies suggest that, the study drug, Everolimus (RAD001), may prevent
      tumor cell growth and also may increase the efficacy of other chemotherapy drugs. Everolimus
      is approved for use in the United States for certain types of cancer, such as kidney cancer.
      It has been extensively studied in people with various types of cancer as a single agent (a
      drug that is used alone to treat the cancer) or in combination with a number of other drugs.
      Studies in adults with cancer have also evaluated Everolimus in combination with other
      anti-tumor drugs. Information from lab studies and some other clinical trials suggests that
      Everolimus may kill leukemia cells on its own, and also make it more likely that steroids
      (such as prednisone) are able to kill leukemia cells.

      In this research study, we are looking to learn more about how Everolimus works in
      combination with other drugs which are commonly used to treat relapsed acute lymphoblastic
      leukemia (prednisone, vincristine, PEG-asparaginase, and doxorubicin). The main goal of the
      study is to evaluate the side effects of this treatment combination in order to determine a
      safe dose of Everolimus which can be given with these other 4 drugs.
    

Detailed description: 
      Study Treatment: The study treatment lasts 32 days during which time you will be taking the
      study drug Everolimus daily for 32 days in addition to standard chemotherapy drugs. Below
      lists the study drug as well as the other drugs you will be receiving to treat your leukemia
      during this research study.

      Chemotherapy drugs:

        1. Everolimus (RAD001): By mouth Daily 1-32

        2. Prednisone: By mouth or in the vein Three times daily on days 4-32

        3. Vincristine: In the vein Daily on days 4, 11, 18, and 25

        4. Doxorubicin: In the vein Once per day on days 4 and 5. A drug called dexrazoxane will be
           given with each dose of Doxorubicin to protect the heart from any damage that might be
           caused by Doxorubicin.

        5. PEG-asparaginase: In the vein Once per day on days 5 and 18

      If you have or have had an allergy to PEG-asparaginase, we will give another form of
      asparaginase (Erwinia asparaginase). Four doses of Erwinia asparaginase will be given in the
      muscle twice a week beginning on Day 5 and then another 4 doses will be given in the muscle
      twice a week beginning on Day 15 in place of the scheduled doses of PEG-asparaginase.

      In addition to the medications listed above, you will also be receiving intrathecal (IT)
      chemotherapy that is given directly into your spinal fluid to treat the leukemia that may
      have spread to your brain and spinal fluid. The medicines we will be giving in your spinal
      fluid are listed below. The number of times we give chemotherapy into the spinal fluid will
      depend on whether or not we see leukemia cells in your spinal fluid on the sample we take on
      the first day of the study.

        1. Cytarabine on Day 1 (also Day 4 if we see leukemia cells in your spinal fluid on the
           screening spinal tap)

        2. Triple intrathecal therapy (cytarabine, methotrexate and hydrocortisone)on Days 18 and
           32 (if we do not see leukemia cells in your spinal fluid on the screening spinal tap),
           or on Days 11, 18, 25 and 32 (if we see leukemia cells in your spinal fluid on the
           screening spinal tap)

      A drug called leucovorin will be given by mouth or by vein after each dose of triple
      intrathecal therapy. Leucovorin is given to prevent mouth sores which might occur after you
      get methotrexate in the spinal fluid. Leucovorin will be given three times a day for 24 hours
      beginning one day after you receive a dose of triple intrathecal therapy.

      Portions of this treatment are "routine" or "standard" ways of treating recurrent ALL.
      Receiving vincristine, prednisone, PEG asparaginase and doxorubicin along with chemotherapy
      in the spinal fluid is a standard treatment for relapsed leukemia. The research part of the
      treatment involves giving Everolimus at the same time as these drugs.

      Clinical and Lab Exams: During the study, you will have a physical examinations and you will
      be asked questions about your general health and specific questions about any problems that
      you might be having and any medications you may be taking. You will also have blood work to
      check for any side effects to your organs from the study drug and other chemotherapy drugs.
      Bone marrow studies will be done at the end of the 32-day treatment period to assess how you
      responded to treatment. If you are in remission, a special minimal residual disease (MRD)
      test will also be performed from the marrow sample as part of the study.
    

Intervention name(s): Everolimus; Prednisone; Vincristine; PEG-Asparaginase; Doxorubicin; Dexrazoxane
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): Orally, daily days 1-32 per assigned dose level; 40 mg/m2/day orally 3 x daily days 4-32; 1.5 mg/m2 IV daily on days 4, 11, 18, and 25; 2,500 U/m2 IV 1 x daily on days 5 and 18; 30 mg/m2 IV on days 4 and 5; 300 mg/m2 IV on days 4 and 5
Other intervention name(s): RAD-001; Oncaspar; Zinecard
Intervention MeSH terms: Prednisone; Doxorubicin; Dexrazoxane; Vincristine; Everolimus; Asparaginase; Pegaspargase; Razoxane
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: ALL; pediatric; relapse